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Background: The epidermal growth factor receptor family is expressed in breast cancer, and agents targeting this
pathway have single agent effects (e.g. traztuzumab). Development of resistance may be due to the presence of
alternative pathways, particularly activation of the PI3K/Akt/MTOR pathway. We have therefore examined the effect
of inhibitors of this pathway (ZSTK474 and sirolimus) in combination with the epidermal growth factor (EGFR)
inhibitors erlotinib and gefitinib in breast MCF10a isogenic cell lines with EGFR, BRAF, AKT, and PI3K mutations.
Results: PI3K mutation conferred increased activity of EGFR inhibitors against MCF10a cells in comparison with the
parental cell line and other mutations studied. Combination of EGFR inhibitors with either the PI3K inhibitor
ZSTK474 or the MTOR inhibitor sirolimus showed increased activity.
Conclusions: These results are encouraging for the use of combinations targeting the PI3K and EGFR pathway simultaneously.
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Molecular alterations such as mutations or amplifications
in Human Epidermal Growth Factor Receptors (HER) or
downstream second messengers such as BRAF, AKT or
PIK3CA can constitutively activate growth pathways in
various cancers (Figure 1). Deregulated signalling through
RAS-RAF-MAPK and PI3K-PTEN-AKT-mTOR path-
ways via such genetic alterations can result in unrestricted
cellular proliferation and increased cell survival. It is for
this reason that the development of drugs that specifically
target these pathway components has become so popular.
Tumours exhibiting mutations within RTK pathway con-
stituents (e.g. RAS, RAF, PIK3CA, PTEN, AKT, mTOR) or
their upstream receptors have shown altered sensitivity to
many different pathway targeted inhibitors including
trastuzumab (Herceptin™) in breast cancer, gefitinib
(Iressa™) in non small cell lung cancer (NSCLC), cetuxi-
mab (Erbitux™) in colorectal cancer (CRC) and vemura-
fenib (Zelboraf™) in skin melanoma when compared to
their wild type counterparts. This has led to a stratified* Correspondence: i.a.cree@warwick.ac.uk
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unless otherwise stated.approach to cancer treatment within those cancers
where a prognostic benefit has been identified with or
without the presence of specific activating mutations.
Inhibition of a solitary signal transduction pathway is
often inefficient due to the development of resistance
through activation of alternative signalling cascades or
receptor switching [1,2]. Data from NSCLC suggests that
sensitivity to anti EGFR therapy is due to activating mu-
tations within EGFR, which are not present in breast
cancer. However, it has also been suggested that anti-
EGFR strategies may also fail due to the presence of al-
ternate activated pathways in which alternative activating
mutations may be present. In breast cancer, HER2 amp-
lification is used to guide the use of trastuzumab, an
antibody to HER2, and lapatinib, a dual EGFR and HER2
small molecule targeted agent. Resistance to trastuzu-
mab and lapatinib has been linked to aberrations of the
PI3K pathway [3]. PI3K abnormalities including activat-
ing mutation of PIK3CA and loss of PTEN are common
in breast cancer [3-6]. Other resistance mechanisms in-
clude activation of alternate pathways, particularly those
involving IGF and HER3 [7-9].
To better understand how different activating mutations
affect the sensitivity of RTK pathway targeted inhibition,
we tested a set of human non-tumorigenic immortalized
breast epithelial cells (MCF10a, obtained from Horizonl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Human epidermal growth factor receptor and PI3K pathways in breast cancer.
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EGFR, BRAF, AKT and PI3K along with the parental line
which is wild type for these mutations against growth fac-
tor pathway inhibitors.
This isogenic cell line technology used here was initially
developed by Di Nicolantonio and colleagues when a
panel of isogenic human cell lines were created by
employing homologous recombination (by knock-in) to
characterize the response of the specific mTOR inhibitor
everolimus to those cells containing specific mutations
[10]. Using paired cell lines (isogenic and parental); drug
sensitivity versus resistance was accurately assessed, with
any phenotypic changes being a direct result of the intro-
duced mutations. The DNA-modifications made to these
commercially available cell lines are made within the en-
dogenous gene so as to closely recapitulate the genetic
events leading to the desired disease of study, or in our
case to the effect of drugs targeting altered pathways.
In this study we have used a comparative approach.
Mutant and wild type (Wt) MCF10a cells were tested for
sensitivity against EGFR/PI3K/mTOR pathway inhibitors
gefitinib (Iressa), erlotinib (Tarceva), sirolimus (Rapamy-
cin) and ZSTK474, a pan-PI3K inhibitor as single agents
and in combination [11].Methods
Cell lines
Isogenic MCF10a cell lines with mutations in EGFR,
BRAF, AKT and PI3K obtained from Horizon Diagnostics
(Cambridge) were tested for sensitivity to these targeted
inhibitors and compared with their parental MCF10a cell
line. The MCF10a parent cell line (also available from
ATCC) is immortalised, and was originally grown from
adherent epithelia cells from a patient said to have fibro-
cystic disease. It was chosen by Horizon discovery for
their X-man technology as it is easily transfected. It is
non-tumorigenic, but does not exhibit senescence. Intro-
duction of new mutations into this line does change its
characteristics [12,13] and we believe it to be a good model
of the generic effects of PI3K and EGFR inhibition in
breast epithelium. Cell lines were grown in accordance
to manufacturers’ guidelines. All were grown in DMEM:F12
medium with 5% horse serum, antibiotics (100 units/ml
penicillin and 0.1 mg/ml streptomycin), 2 mM L-glutamine,
0.01 mg/ml insulin, 500 ng/ml hydrocortisone, 100 ng/ml
cholera toxin, and 20 ng/ml EGF. Cell lines were grown
adherent to plastic in 75 cm2 tissue culture flasks (Fisher
Scientific UK; TKV-123-031 L and passaged at regular in-
tervals when they reached 90% confluence. Cells for
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and washed twice in serum-free complete assay medium
(CAM) before plating for chemosensitivity assays.
ATP-TCA
The ATP-Based tumour chemosensitivity assay (ATP-TCA)
was performed as previously described [14,15].
(a) Preparation of chemotherapeutic agents
Gefitinib, erlotinib, ZSTK474 and sirolimus were
purchased from LC Laboratories (Massachusetts,
US). All drugs were diluted in CAM (Innovative
Diagnostik-systeme) to concentrations thought to be
clinically achievable (gefitinib 0.06-2 μM, erlotinib
0.2-6.5 μM, ZSTK474 0.07-2.2 μM, sirolimus
0.06-2 μM). Combinations were tested by
simultaneous addition. All of the chemotherapeutic
drugs or combinations were tested in triplicate at 6
dilutions in 96-well round-bottomed polypropylene
microplate (Corning Life Sciences, UK; 3790),
allowing four drugs or drug combinations were
tested. Two controls were included in one row of
each plate: a no drug control consisting of media
only (MO) and a maximum inhibitor (MI) control
which kills all cells present giving a zero ATP count.
(b) ATP extraction and measurement
ATP was extracted from cells by the addition of 50 μl
of ATP extraction reagent (DCS) to each well of
the 96-well plate. Plates were incubated at room
temperature for a minimum of 20 minutes and a
maximum of one hour before the ATP was read.
The ATP in the wells was measured using a
luciferin-luciferase counting reagent as previously
described [14,15]. Light output was measured using
a Berthold Diagnostic Systems MPL1 luminometer
(Berthold Diagnostic Systems, Pforzheim, Germany).
All luminescence measurements were performed
using the manufacturer’s instructions and an ATP
standard curve run before each read using
Adenosine 5’-triphosphate standard disodium salt
hydrate (Sigma).
(c) Viability analysis
The data produced from each ATP-TCA plate was
entered into an Excel (Microsoft®) spreadsheet
that calculated the percentage tumour growth
inhibition at each concentration, the IC50, and
IC90 (concentration of drug required to cause 50%
and 90% inhibition) for each drug as described in
[14,15]. The percentage tumour growth inhibition
at each drug concentration was used to plot curves
for each drug or combination. As the variation
between the wells that were averaged to calculate
the percentage tumour inhibition is small (typical
coefficient of variance of less than 10%), error barshave not been included on most graphs as they are
usually smaller than the markers on the graphs.
The percentage tumour growth inhibition was
calculated as follows:% Inhibition ¼ 1:0 − Test−MIð Þ  100
MO−MIð Þ
Test = mean counts for test drug wells
MI =mean counts for maximum inhibitor wells
MO =mean counts for medium only wells
To allow comparison between different cell lines, a
sensitivity index (IndexSUM) was used to calculate
sensitivity based on percentage inhibition for each
drug or combination, where IndexSUM= Sum
(Inhibition200….6.25%).
The effects of drug combinations compared with
their single agent counterparts were analysed using
combination indices. Combination indices (CI)
calculated by the Chou and Talalay [16] methods
were determined at 50% and 90% cell death. These
were defined as follows:CIAþ B ¼ DA=Aþ Bð Þ=DA½  þ DB=Aþ Bð Þ=DB½  þ
α DA=Aþ B x DB=Aþ Bð Þ=DADB½ 
Where CIA + B = CI for a fixed effect (F = 50% or
90%) for the combination of cytotoxic A and
cytotoxic B; DA/A + B = concentration of cytotoxic
A in the combination A + B giving an effect F;
DB/A + B = concentration of cytotoxic B in the
combination A + B giving an effect F; DA =
concentration of cytotoxic A alone giving an effect
F; DB = concentration of cytotoxic B alone giving an
effect F. α = parameter with value 0 when A and B
are mutually exclusive and 1 when A and B are
mutually non-exclusive. The combination index CI
calculates synergism <0.8; additivity >0.8 and <1.2;
antagonism >1.2 [17].Mutation analysis
For DNA extraction, the Ambion® RecoverALL™ Nucleic
acid Isolation kit using their total nucleic acid isolation
protocol was used with RNase, according to the manu-
facturer’s instructions. Samples were quantified and pur-
ity checked using 1.5 μl of each undiluted sample with
the NanoDrop spectrophotometer.
Rapid mutation screening for common mutations in
EGFR, PI3K and BRAF was performed using Therasc-
reen (Qiagen) kits, according to the manufacturer’s in-
structions. PCR was performed in an AB 7500 Fast Dx
PCR machine and results downloaded to an Excel
spreadsheet for analysis.
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The ATP-TCA was used to determine the effect of EGFR
inhibitors (gefitinib and erlotinib) alone and in combin-
ation with inhibitors of the Akt/PI3K/mTOR pathway.
Effect of single agents on isogenic MCF10a cell lines
(a) EGFR inhibitorsFig
cell
600The parental MCF10a cell line showed greater
resistance to gefitinib than those with mutations in
EGFR, KRAS, PI3K, BRAF and AKT (Figure 2).
Greatest sensitivity was seen within the PI3K
mutated cells where IndexSUM values decreased from a
relatively resistant index of 423 to 120 and 64 for the
H1407R and E545K mutations of PI3KCA respectively.
MCF10a cells were more sensitive to erlotinib
(IndexSUM = 188) than gefitinib (IndexSUM = 423).
Changes in sensitivity caused by the mutations were
less pronounced in response to erlotinib exposure.
The PIK3CA mutation E545K still became the most
sensitive phenotype, but the effect of an AKT
mutation produced a slightly more resistant
phenotype (IndexSUM = 227) when compared with the
parental line (IndexSUM = 188). However, both showed
sufficient cellular inhibition to be classed as active
agents in this setting with an indexSUM <300
representing 50% inhibition across the range of
concentrations tested [18].ure 2 Sensitivity of gefitinib, erlotinib, ZSTK474 and sirolimus al
line compared with isogenic clones with EGFR, KRAS and PI3K
= no inhibition.(b) PI3K inhibitor
All mutated MCF10a cell lines showed sensitivity to
the PI3K inhibitor ZSTK474 (IndexSUM < 300) with
EGFR and AKT mutations having no effect on the
activity of this agent. Results with these mutations
were similar to the parental line. PI3K mutations
conferred greater sensitivity to ZSTK474 compared
with the parental line, while cells containing the
BRAF mutation V600E showed a more resistant
phenotype.
(c) mTOR inhibitor
Sirolimus was the least active of the four inhibitors
tested (Figure 2). Only MCF10a cells harbouring
EGFR and PIKCA (E545K) mutations showed
sensitivity with IndexSUM of 272 and 254
respectively which was an increase compared with
the parental line IndexSUM of 333. BRAF mutation
containing cells (V600E) again showed the most
resistant phenotype with an IndexSUM of 533.
Effect of combinations on isogenic MCF10a cell lines
Combination of the EGFR inhibitors with either ZSTK474
or sirolimus resulted in greatly increased cellular inhib-
ition (Figure 2), with sensitivity IndexSUM values in all
MCF10a cell lines below 200 and corresponding CI indi-
ces (Table 1). The effects of mutations on sensitivity were
observable with cells containing BRAF mutations, though
these showed less sensitivity to combinations whenone and in combination on the parental MCF10a breast cancer
mutations. A sensitivity index of zero = complete inhibition,

















Cell Line C150 C190
MCF10a Wt 0.23 0.58 0.02 0.28 0.47 0.42 0.03 0.07
MCF10a PI3K (H1047R) 1.15 0.93 1.09 0.89 0.18 0.39 0.46 0.40
MCF10a PI3K (E545K) 1.15 1.41 1.52 1.30 0.41 0.75 0.32 0.44
MCF10a EGFR (Δ E746-A750) 0.40 0.93 0.60 1.10 0.30 0.27 0.04 0.09
MCF10a BRAF (V 600E) 0.93 1.18 0.59 1.07 0.35 0.19 1.04 1.33
MCF10a Akt (E17K) 0.37 0.51 0.20 0.33 0.18 0.18 0.05 0.08
The combination index CI calculates synergism <0.8; additivity >0.8 and <1.2; antagonism >1.2. Synergism is noted in the wild type cell line, and in the Akt
mutated line while there is some indication of antagonism in one PI3K mutated line.
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the PI3K mutation H1047R showed little sensitivity to sin-
gle agent sirolimus, and in combination with EGFR inhibi-
tors were still seen to be more resistant than their parental
counterpart, and were more resistant than MCF10a cells
containing the PIK3CA E545K mutation.
Mutation status of MCF10a cell lines
MCF10a cell lines included mutations in EGFR (exon 19
deletion E746-A750), BRAF (c.1799 T > A–V600E), PI3K
(c.3140A >G–H1047R and c.1633G >A–E545K) and AKT
(c.49G >A–E17K). All cell line mutations were confirmed
where Therascreen ARMS kits for the relevant mutation
were available (Qiagen Ltd, Manchester): confirmation was
obtained for all but the AKT mutation, which was not
available as a Therascreen kit. The parental MCF10a cell
line was also screened against all available mutation tests to
confirm mutation exclusion.
Discussion
Variation in sensitivity was seen with different mutations
for all four single agents. Cells with PIK3CA mutations
H1047R and E545K showed greatest single agent sensi-
tivity to the PI3K inhibitor. Interestingly, cells with these
mutations also showed greater sensitivity to gefitinib and
erlotinib than cells with the EGFR mutation (exon 19
deletion), which are associated with sensitivity to EGFR
inhibitors in NSCLC. Mutations in PI3K (H1047R) have
been shown to enhance HER2-mediated transformation
by amplifying the ligand-induced signaling output of the
HER family of RTKs [19]. It could be therefore be as-
sumed that because PIK3CA mutations drive HER re-
lated receptor addiction in these cells it would make
them more susceptible to RTK inhibition (as seen here
with gefitinib and erlotinib) (Figure 1).
Cells containing the PIK3CA mutation E545K were
found to be more sensitive than those with the PIK3CA
mutation H1047R, suggesting that not all activating mu-
tations found within a given gene will result in the sameactivity to targeted therapy. Equally cells with activating
mutations can react differently to inhibitors of the same
target. This is seen here with EGFR mutants as cells with
EGFR mutation were significantly more susceptible to
erlotinib compared with gefitinib. In reality not all acti-
vating mutations within a given gene are comparable in
their effect, as has been shown in other tumour types.
For instance, it has been suggested that not all KRAS
mutations in colorectal cancer are equally effective in
conferring resistance to anti-EGFR antibodies [10].
Least inhibition from exposure to the mTOR inhibitor
sirolimus was seen in the presence of the BRAF muta-
tion V600E. This is unsurprising given that inhibition of
mTOR by sirolimus drives signalling through alternative
pathways (AKT/PI3K or MEK/ERK) resulting in hyper-
activation of the RAS/RAF/MAPK pathway due to the
presence of the BRAF mutation [20-22].
The most effective combinations were of EGFR and
PI3K inhibitors. In the presence of gefitinib, PI3K signal-
ling can be maintained by an activated IGF1R pathway
[23,24]. Therefore it could be suggested that for single
agent anti-EGFR therapy to remain effective it would re-
quire cells to have EGFR dominant HER signalling in
the absence of IGFR signalling pathways. In anti-EGFR
resistant tumours showing this profile further alternate
signalling mechanisms may be employed, including con-
tinued signalling via Met by driving HER3 dependent ac-
tivation of PI3K. Therefore the combinational strategy of
EGFR and PI3K takes advantage of any further down-
stream signalling through PI3K and is found to be effect-
ive despite which mutation is present.
Conclusions
In breast cancer, there has been considerable interest in
the combination of PI3K pathway inhibitors with anti-
HER2 therapy. Data from different cell lines have been
used to justify this [25], but this is to our knowledge
the first report using a single parental cell line. Clinical
trials are now in progress, and early results are
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mTOR inhibitors [26]. PI3K inhibitors are also entering
clinical trials in combination with HER2 inhibitors [27].
The data presented here support these trials, and sup-
port the importance of full molecular characterisation
of tumours where possible, suggesting that a more ef-
fective strategy in the use of pathway-targeted treat-
ment may come from using the agents in combination
to secure a strong signalling blockade.
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